Showing 491-500 of 7745 results for "".
VShape Facial Contouring by Alma Lasers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/vshape-facial-contouring-by-alma-lasers/19251/VShape is a non-invasive and pain-free treatment for facial contouring. Performed throughout the world using Alma Lasers Accent Ultra medical aesthetic technology. vShape: Bipolar RF TechnologyFrom Clinic to Capitol: Tips for Building Grassroots and Legislative Support For Anti-Tanning Policies in Your State
https://practicaldermatology.com/topics/skin-cancer-photoprotection/from-clinic-to-capitol-tips-for-building-grassroots-and-legislative-support-for-anti-tanning-policies-in-your-state/22943/It's no easy task to shepherd legislation through state assemblies, but dermatologists' clinical standing can have some influence.All Things Psoriasis With Dr. April Armstrong
https://practicaldermatology.com/series/the-practical-dermatology-podcast/all-things-psoriasis-with-dr-april-armstrong/36135/The latest news and updates, plus April W. Armstrong, MD, MPH, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the current state of psoriasis treatments, what's in the pipeline, her experience in leadership positions for multiple psoriasis organizations, and more.Ask Me Anything: Mona Sadeghpour, MD
https://practicaldermatology.com/youngmd-connect/wrap-ups/ask-me-anything-mona-sadeghpour-md/24215/An intimate YoungMD Connect virtual mentorship event encourages exchange of ideas, advice, and feedback.Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.Treating Severe Acne in Transgender Patients: An Update
https://practicaldermatology.com/columns/clinical-focus-1/treating-severe-acne-in-transgender-patients-an-update/23472/Understanding the implications of isotretinoin use in FTM acne patients.FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/series/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.Is this the Golden Age of Hair Loss Treatment?
https://practicaldermatology.com/topics/hair-nails/is-this-the-golden-age-of-hair-loss-treatment/24036/A perfect storm of many new, unrelated scientific developments also has the potential to fundamentally reshape the way we think about a disease or disease group. Dr. Peter C. Friedman believes many recent breakthroughs have profoundly changed how general dermatologists can manage patients with hairAtypical Sweet Syndrome: A Case Report and Brief Literature Review
https://practicaldermatology.com/topics/rare-disease/atypical-sweet-syndrome-a-case-report-and-brief-literature-review/23610/A case highlights the complexity of this diagnosis, including its management and workup, especially when pathology findings are atypical.FDA Approves Axillary Hyperhidrosis Treatment; Study Examines Biologic Outcomes in Psoriasis
https://practicaldermatology.com/series/dermwire-tv/fda-approves-axillary-hyperhidrosis-treatment-study-examines-biologic-outcomes-psoriasis/26562/In this week's DermwireTV, the FDA approves a first-of-its-kind gel for axillary hyperhidrosis; a new analysis examines how smoking, BMI, and age affect biologic outcomes in psoriasis; and the CEO of Aerolase joins us to discuss the latest trends in the aesthetic laser market.